AbbVie Gains on Positive Phase 3 Results for Multiple Myeloma Treatment

Key Facts

In a move reflecting the ongoing evolution of the biopharmaceutical sector, AbbVie announced positive topline results from the Phase 3 CERVINO trial of etentamig for relapsed/refractory multiple myeloma. The drug achieved a 74% objective response rate and significantly reduced the risk of disease progression or death by 60% compared to standard available therapies. According to reports, the trial focused on triple-class exposed patients, highlighting the drug's differentiated clinical profile in addressing unmet medical needs.

These results bolster AbbVie's position in the competitive oncology market, as the drug demonstrated lower rates of severe side effects during the study. Per market data, ABBV stock closed at $261.70 on September 2, 2026, after reaching a day high of $262.97. This performance underscores the company's stability as investors weigh the potential for future revenue growth and regulatory approvals following successful clinical milestones.

At the close of September 2, 2026, ABBV was priced at $261.70, with technical support observed near the daily low of $257.70. Market participants are now looking forward to the presentation of full trial results at the International Myeloma Society Annual Meeting later this month. Additionally, traders are monitoring upcoming macroeconomic catalysts, including a scheduled speech by Fed Chair Kevin Warsh, which could influence broader market sentiment for large-cap healthcare stocks.